Progress towards the UNAIDS 95-95-95 targets in the Fifth Botswana AIDS Impact Survey (BAIS V 2021): a nationally representative survey.


Journal

The lancet. HIV
ISSN: 2352-3018
Titre abrégé: Lancet HIV
Pays: Netherlands
ID NLM: 101645355

Informations de publication

Date de publication:
08 Mar 2024
Historique:
received: 11 05 2023
revised: 18 12 2023
accepted: 03 01 2024
medline: 12 3 2024
pubmed: 12 3 2024
entrez: 11 3 2024
Statut: aheadofprint

Résumé

In 2014, UNAIDS set a goal to end the AIDS epidemic by achieving targets for the percentage of people living with HIV who were aware of their status, on antiretroviral therapy (ART), and virally suppressed. In 2020, these targets were revised to 95% for each measure (known as 95-95-95), to be reached among people living with HIV by 2025. We used data from the Fifth Botswana AIDS Impact Survey (BAIS V) to measure progress towards these testing and treatment targets in Botswana. BAIS V used a two-stage cluster design to obtain a nationally representative sample of people aged 15-64 years in Botswana. During March-August, 2021, 14 763 consenting participants were interviewed and tested for HIV in their households by survey teams. HIV-positive specimens were tested for viral load, presence of antiretroviral drugs, and recency of infection using the HIV-1 limiting antigen avidity enzyme immunoassay. Estimates of HIV-positive status and use of ART were based on self-report and the analysis of blood specimens for antiretroviral drugs. Viral load suppression was defined as an HIV RNA concentration of less than 1000 copies per mL. HIV incidence was calculated using the recent infection testing algorithm. Data were weighted to account for the complex survey design. The national HIV prevalence in Botswana among people aged 15-64 years was 20·8% and the annual incidence of HIV infection was 0·2%. 95·1% (men 93·0%, women 96·4%) of people living with HIV aged 15-64 years were aware of their status, 98·0% (men 97·2%, women 98·4%) of those aware were on ART, and 97·9% (men 96·6%, women 98·6%) of those on ART had viral load suppression. Among young people (aged 15-24 years) living with HIV, 84·5% were aware of their status, 98·5% of those aware were on ART, and 91·6% of those on ART had viral load suppression. The prevalance of viral load suppression among all people living with HIV was 91·8%, and varied by district-ranging from 85·3% in Gaborone to 100·0% in Selibe Phikwe. BAIS V is the first population-based survey worldwide to report the achievement of the UNAIDS 95-95-95 goals, both overall and among women. Strategies to reach undiagnosed men and young people, including young women, are needed. US President's Emergency Plan for AIDS Relief.

Sections du résumé

BACKGROUND BACKGROUND
In 2014, UNAIDS set a goal to end the AIDS epidemic by achieving targets for the percentage of people living with HIV who were aware of their status, on antiretroviral therapy (ART), and virally suppressed. In 2020, these targets were revised to 95% for each measure (known as 95-95-95), to be reached among people living with HIV by 2025. We used data from the Fifth Botswana AIDS Impact Survey (BAIS V) to measure progress towards these testing and treatment targets in Botswana.
METHODS METHODS
BAIS V used a two-stage cluster design to obtain a nationally representative sample of people aged 15-64 years in Botswana. During March-August, 2021, 14 763 consenting participants were interviewed and tested for HIV in their households by survey teams. HIV-positive specimens were tested for viral load, presence of antiretroviral drugs, and recency of infection using the HIV-1 limiting antigen avidity enzyme immunoassay. Estimates of HIV-positive status and use of ART were based on self-report and the analysis of blood specimens for antiretroviral drugs. Viral load suppression was defined as an HIV RNA concentration of less than 1000 copies per mL. HIV incidence was calculated using the recent infection testing algorithm. Data were weighted to account for the complex survey design.
FINDINGS RESULTS
The national HIV prevalence in Botswana among people aged 15-64 years was 20·8% and the annual incidence of HIV infection was 0·2%. 95·1% (men 93·0%, women 96·4%) of people living with HIV aged 15-64 years were aware of their status, 98·0% (men 97·2%, women 98·4%) of those aware were on ART, and 97·9% (men 96·6%, women 98·6%) of those on ART had viral load suppression. Among young people (aged 15-24 years) living with HIV, 84·5% were aware of their status, 98·5% of those aware were on ART, and 91·6% of those on ART had viral load suppression. The prevalance of viral load suppression among all people living with HIV was 91·8%, and varied by district-ranging from 85·3% in Gaborone to 100·0% in Selibe Phikwe.
INTERPRETATION CONCLUSIONS
BAIS V is the first population-based survey worldwide to report the achievement of the UNAIDS 95-95-95 goals, both overall and among women. Strategies to reach undiagnosed men and young people, including young women, are needed.
FUNDING BACKGROUND
US President's Emergency Plan for AIDS Relief.

Identifiants

pubmed: 38467135
pii: S2352-3018(24)00003-1
doi: 10.1016/S2352-3018(24)00003-1
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests We declare no competing interests.

Auteurs

Madisa Mine (M)

Ministry of Health, Gaborone, Botswana.

Kristen A Stafford (KA)

Center for International Health, Education, and Biosecurity, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.

Rebecca L Laws (RL)

Division of Global HIV and TB, US Centers for Disease Control and Prevention, Atlanta, GA, USA.

Reson Marima (R)

Botswana University of Maryland School of Medicine Health Initiative (Bummhi), Gaborone, Botswana.

Phenyo Lekone (P)

Division of Global HIV and TB, US Centers for Disease Control and Prevention, Gaborone, Botswana.

Dinah Ramaabya (D)

Ministry of Health, Gaborone, Botswana.

Kgomotso Makhaola (K)

Division of Global HIV and TB, US Centers for Disease Control and Prevention, Gaborone, Botswana.

Hetal K Patel (HK)

Division of Global HIV and TB, US Centers for Disease Control and Prevention, Atlanta, GA, USA.

Prichard Mapondera (P)

Botswana University of Maryland School of Medicine Health Initiative (Bummhi), Gaborone, Botswana.

Floris Wray-Gordon (F)

Division of Global HIV and TB, US Centers for Disease Control and Prevention, Atlanta, GA, USA.

Chinedu Agbakwuru (C)

Center for International Health, Education, and Biosecurity, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.

Lillian Okui (L)

Botswana University of Maryland School of Medicine Health Initiative (Bummhi), Gaborone, Botswana.

Susan Matroos (S)

Statistics Botswana, Gaborone, Botswana.

Eden Onyadile (E)

Statistics Botswana, Gaborone, Botswana.

Julia Ngidi (J)

Ministry of Health, Gaborone, Botswana.

Alash'le Abimiku (A)

Center for International Health, Education, and Biosecurity, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.

Khuteletso Bagapi (K)

Division of Global HIV and TB, US Centers for Disease Control and Prevention, Gaborone, Botswana.

Bornapate Nkomo (B)

Ministry of Health, Gaborone, Botswana.

Stephane M Bodika (SM)

Division of Global HIV and TB, US Centers for Disease Control and Prevention, Atlanta, GA, USA.

Kaylee J Kim (KJ)

Division of Global HIV and TB, US Centers for Disease Control and Prevention, Gaborone, Botswana.

Mirna Moloney (M)

Center for International Health, Education, and Biosecurity, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.

Andrew Mitchell (A)

Center for International Health, Education, and Biosecurity, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.

Akipu Ehoche (A)

Center for International Health, Education, and Biosecurity, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.

Faith L Ussery (FL)

Division of Global HIV and TB, US Centers for Disease Control and Prevention, Atlanta, GA, USA.

Steven Y Hong (SY)

Division of Global HIV and TB, US Centers for Disease Control and Prevention, Gaborone, Botswana.

Stella Keipeile (S)

National AIDS and Health Promotion Agency, Gaborone, Botswana.

Matshelo Matlhaga (M)

National AIDS and Health Promotion Agency, Gaborone, Botswana.

Rapetse Mathumo (R)

National AIDS and Health Promotion Agency, Gaborone, Botswana.

Robert Selato (R)

National AIDS and Health Promotion Agency, Gaborone, Botswana.

Manhattan E Charurat (ME)

Center for International Health, Education, and Biosecurity, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.

Andrew C Voetsch (AC)

Division of Global HIV and TB, US Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: avoetsch@cdc.gov.

Classifications MeSH